Interferon Gamma-Primed MSCs for GVHD Prophylaxis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacologic prophylaxis and therapeutics for graft versus host disease (GVHD) in hematopoietic cell transplantation are only partially effective, increasing the risk of infection and disease relapse, and impart significant short- and long-term adverse effects.
Innovation Solution
Administration of interferon γ-primed mesenchymal stromal cells (γMSCs), which are manufactured and administered to patients undergoing hematopoietic stem cell transplantation to provide potent GVHD prophylactic activity without adverse effects, by priming MSCs with interferon γ in a non-hypoxic culture condition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmacologic GVHD prophylaxis and therapeutics are administered, then GVHD prevention is improved, but the risk of infection and disease relapse increases and adverse effects occur
Solution Approach 1:
The patent uses mesenchymal stromal cells (MSCs) as an intermediary biological agent to mediate immune modulation and prevent GVHD. These cells act as a bridge between the donor graft and host, suppressing pathological immune responses without the harmful side effects of pharmacologic agents. The MSCs interact with immune cells to modulate their function, providing protection against GVHD while maintaining immune surveillance against infections and disease relapse.
Solution Approach 2:
The patent applies interferon gamma (IFNγ) to prime the MSCs, fundamentally changing their functional parameters. This priming process upregulates specific surface markers (such as HLA-DR, CD80, CD86) and enhances the cells' immune modulatory capabilities. The parameter change transforms standard MSCs into highly potent GVHD-prophylactic cells that maintain reduced infection risk and disease relapse compared to drug-based approaches.
2Reliability
If pharmacologic GVHD prophylaxis and therapeutics are administered, then GVHD prevention is improved, but drug-related adverse effects occur
Solution Approach 1:
The patent replaces pharmacologic mediators with biological mediators (MSCs). Instead of using drugs that directly suppress immune function and cause adverse effects, the patent employs MSCs as natural biological mediators that modulate immune responses through cell-to-cell interactions and secretion of regulatory molecules. This intermediary approach achieves GVHD prevention without the toxic side effects associated with conventional drugs.
Solution Approach 2:
The primed MSCs possess inherent immune modulatory capabilities that are enhanced through IFNγ treatment. These cells serve themselves by autonomously regulating immune responses, suppressing activated T cells, and creating an immunomodulatory environment without requiring external pharmacologic support. This self-service mechanism eliminates drug-related adverse effects while maintaining effective GVHD prophylaxis.
Data Source
AI summary
The present disclosure provides composition and methods comprising interferon γ-primed human mesenchymal stromal cells (γMSCs) for preventing or reducing the likelihood of Graft Versus Host Disease (GVHD) or a symptom thereof in a human subject that has been administered a hematopoietic stem cell transplant (HCT).